Fig. 3.

SR1 treatment inhibits tumor growth in a xenotransplantation model of imatinib-resistant GIST. Eight weeks of treatment with SR1 significantly decreased GIST430 xenograft growth compared with IgG control treatment (A). Representative images of SR1 and IgG control-treated mice are shown (B). Fluorescent microscopy was used to evaluate the presence of GFP-positive growths after animal sacrifice (C). The identity of GIST430 xenotransplanted tumors was confirmed by H&E staining and by IHC for GIST markers KIT and DOG1 (D).